Year In Review Schizophrenia

UTI Treatment Leads to Fatal Drug Interaction in a Schizophrenia Patient

By November 23, 2016

This case is the first to describe a fatal outcome with such an interaction.

Can Exenatide Help with Weight Loss in Antipsychotic-Treated Schizophrenia Patients?

October 05, 2016

No significant difference in weight loss for obese patients treated with exenatide, placebo

ADHD in Schizophrenia Patients: Recommendations for Managing a Common Comorbidity

By September 29, 2016

Not only is it difficult to diagnose patients who suffer from both of these disorders, treatment is challenging due to the controversial evidence regarding appropriate therapy.

Preventing Relapse in Schizophrenia: Oral vs. Long-Acting Injectable Therapies

By August 25, 2016

Periods of relapse often lead to detrimental effects for patients as well as caregivers, therefore it is important to prevent relapse and increase remission time as much as possible.

Study Confirms Lowest Effective Dose for Lurasidone in Schizophrenia

By August 08, 2016

Sunovion announced the publication of data from a randomized, double-blind, placebo-controlled study that evaluated the efficacy of low-dose Latuda (lurasidone HCl) 20mg daily in adults with schizophrenia, and the effect of dose escalation in adults who demonstrated inadequate initial response to standard dose Latuda.

Adjunctive Antidepressant Therapy in Schizophrenia: Is It Beneficial?

July 28, 2016

Researchers investigated the efficacy of individual antidepressants in the treatment of depressive and negative symptoms associated with schizophrenia.

Study Explores Antipsychotic Prescribing Practices, Polypharmacy

July 22, 2016

Diagnosis of schizophrenia, length of stay of 90 days or more are strongest predictors of polypharmacy

Benefits, Safety of Paliperidone Injectable vs. ER Tablet Compared for Schizophrenia Maintenance

By July 21, 2016

An analysis published in International Clinical Psychopharmacology found that paliperidone palmitate once-monthly (PP1M) had a more favorable benefit-risk profile compared to oral paliperidone extended-release (ER) in the maintenance treatment of schizophrenia through Week 40.

Drug Combo May Improve Psychopathology, Lower BMI in Schizophrenia Patients

By July 18, 2016

Co-treatment with topiramate and an antipsychotic significantly decreased total, positive, negative, and general psychopathology and weight/body mass index (BMI) in patients with schizophrenia spectrum disorder while being well tolerated, a meta-analysis in the Journal of Clinical Psychology reported.

Managing Antipsychotic-Induced Somnolence: A Review

By July 05, 2016

Antipsychotic-induced somnolence should be managed with sleep hygiene education, selecting an antipsychotic with a lower risk of somnolence, and initiating at a lower dose with a slower titration based on psychiatric diagnoses, a review published in CNS Drugs stated.

Treating Agitation in Psychotic and Bipolar Disorders: What Works?

June 28, 2016

Agitation is a "common and important clinical management problem" in both major psychotic and mood disorders.

Adding Vitamin D May Reduce Side Effect of Certain Antipsychotic Drugs

By June 02, 2016

Adding vitamin D may lessen the risk of developing new-onset diabetes in patients taking atypical antipsychotics, according to a study published in Scientific Reports.

Fanapt Labeling Expanded to Include Maintenance Treatment in Schizophrenia

By May 27, 2016

The approval was based on the results of the REPRIEVE (Relapse prevention study in patients with schizophrenia) clinical study.

Prenatal Smoking May Up Schizophrenia Risk in Offspring

By May 26, 2016

In the most definitive study to date, cigarette smoking during pregnancy was linked to a greater likelihood of schizophrenia in offspring. Those are the findings of a new long-term study which assessed maternal nicotine exposure (via cotinine levels) during pregnancy.

Sleep Disorders and Psychiatric Illness: A Complex Clinical Challenge

May 26, 2016

Sleep dysfunction is very common among patients diagnosed with psychiatric disorders, but treatment can be tricky.

Study Suggests Antipsychotic Agents May Up MI Risk

By May 16, 2016

Patients taking antipsychotic agents may be at an increased risk of myocardial infarction, based on a review of nine observational studies.

Emerging Treatments in Schizophrenia

April 28, 2016

A recent article by Brown and Roffman reviews emerging targets and adjunctive agents under investigation, which may target the negative symptoms and cognitive impairment associated with schizophrenia.

Do Antioxidants Improve Acute Psychosis in Schizophrenia?

March 21, 2016

A growing body of evidence suggests that progressive changes in brain structure and function occur with the unfolding of schizophrenia.

New Antipsychotic Agent Available for Bipolar Mania, Schizophrenia

By March 16, 2016

Vraylar (cariprazine; Allergan) is now available for the acute treatment of manic or mixed episodes associated with bipolar 1 disorder and for the treatment of schizophrenia in adults.

Antipsychotic Found to Significantly Slow Bowel Motility

By February 24, 2016

Patients treated with the antipsychotic clozapine were found to have delayed colonic transit that was 4 times longer than normal, findings from a new study published in EBioMedicine reported.

Switching from Antipsychotic Polypharmacy to Monotherapy in Schizophrenia: Risks and Benefits

February 22, 2016

Antipsychotic (AP) polypharmacy is common in psychiatric practice, despite concerns about its risks and questions regarding its effectiveness.

Urgent Care: Schizophrenia Patients Dying Prematurely, But Why?

By January 22, 2016

Nonelderly adults with schizophrenia are 3.5 times more likely to die than adults in the general population. Each individual, on average, loses 28.5 years of life.